No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CLPT ClearPoint Neuro
- 5.410
- -0.310-5.42%
Close Jun 14 16:00 ET
- 5.350
- -0.060-1.11%
Post 17:38 ET
148.34MMarket Cap-6518P/E (TTM)
5.630High5.320Low252.37KVolume5.620Open5.720Pre Close1.37MTurnover1.01%Turnover RatioLossP/E (Static)27.42MShares7.97052wk High4.29P/B135.63MFloat Cap4.05052wk Low--Dividend TTM25.07MShs Float31.290Historical High--Div YieldTTM5.42%Amplitude2.860Historical Low5.438Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
ClearPoint Neuro CLPT recently announced the full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System.
ClearPoint Neuro Announces Full Market Release of SmartFrame OR and ClearPoint PRISM 3T Laser Therapy System
ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery from Saturday, June 1st – Tuesday, June 4th in Nashville.
Lake Street Keeps Their Buy Rating on ClearPoint Neuro (CLPT)
We Think Shareholders Are Less Likely To Approve A Pay Rise For ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO For Now
Key Insights ClearPoint Neuro to hold its Annual General Meeting on 15th of May Total pay for CEO Joe Burnett includes US$517.7k salary The overall pay is comparable to the industry average Over
Earnings Call Summary | ClearPoint Neuro(CLPT.US) Q1 2024 Earnings Conference
The following is a summary of the ClearPoint Neuro, Inc. (CLPT) Q1 2024 Earnings Call Transcript:Financial Performance:ClearPoint Neuro reported Q1 2024 total revenue of $7.6 million, a 41% increase c
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2024 Earnings Call Transcript
Comments
$ClearPoint Neuro(CLPT.US$
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
ClearPoint Neuro announced the full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 ASSFN meeting in Nashville from June 1-4.
The SmartFrame OR aims to expand Deep Brain Stimulation (DBS) to more hospitals, making it accessible to more patients. Dr. Kim Burchiel noted that DBS is effective for Parki...
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
ClearPoint Neuro announced the full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 ASSFN meeting in Nashville from June 1-4.
The SmartFrame OR aims to expand Deep Brain Stimulation (DBS) to more hospitals, making it accessible to more patients. Dr. Kim Burchiel noted that DBS is effective for Parki...
$ClearPoint Neuro(CLPT.US$
NEWS
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will present novel research and exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting to be hel...
NEWS
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will present novel research and exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting to be hel...
$ClearPoint Neuro(CLPT.US$ Damn just no volume! Guess FDA ok on stuff for bones dont rate as great as a pill or a shot the deal with the most rare of diseases of all to fight! OVERWEIGHT! Hehehe![]()
2
3
and I’m not saying lifestyle is the only cause of obesity but it is the MAJOR factor.$ClearPoint Neuro(CLPT.US$ Benzinga· 3 mins ago
ClearPoint Neuro Received FDA Clearance For Prism Bone Anchor Accessory
ClearPoint Neuro Received FDA Clearance For Prism Bone Anchor Accessory
1
1
$ClearPoint Neuro(CLPT.US$
NEWS
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patie...
NEWS
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patie...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
